TGA expands SPEVIGO for adolescent GPP care
Australia’s Therapeutic Goods Administration registered SPEVIGO (spesolimab) on 3 February 2026 for generalised pustular psoriasis, including flare treatment and prevention, in adults and adolescents aged 12 years and older who weigh at least 40 kg—a concrete APAC drug-approval update grounded in TGA records.
Contents10 sections
Key Takeaways
- TGA registration decision: SPEVIGO registered 3 February 2026; evaluation started 28 November 2024; decision dated 7 November 2025 (186 of 255 working days).
- Indication covers GPP treatment and flare prevention from age 12 years at ≥40 kg body weight.
- Effisayil 2 (NCT04399837) enrolled 123 patients across 20 countries; high-dose subcutaneous spesolimab cut flare risk versus placebo (HR 0.16).
- ARTG ID 470405 records a SPEVIGO 150 mg/mL pre-filled syringe entry dated 3 February 2026.
SPEVIGO Australia registration at a glance
| Field | Detail |
|---|---|
| Product | SPEVIGO (spesolimab) |
| Sponsor (TGA listing) | Boehringer Ingelheim Pty Ltd |
| ARTG / register date | 3 February 2026 (ARTG 470405 for 150 mg/mL PFS) |
| Indication | GPP, including treatment and prevention of flares; age ≥12 years, weight ≥40 kg |
| Key evidence | Effisayil 1 (NCT03782792); Effisayil 2 (NCT04399837) |
| Region | Australia (ARTG); APAC relevance for rare dermatology access |
What did the TGA decide on SPEVIGO?
According to the TGA prescription medicines registration page for SPEVIGO, Boehringer Ingelheim Pty Ltd is the sponsor, the product was registered on 3 February 2026, and the labelled use is treatment of generalised pustular psoriasis including treatment and prevention of flares in adults and adolescents from 12 years of age weighing at least 40 kg.
The same page records evaluation commencement on 28 November 2024, a decision date of 7 November 2025, and an approval time of 186 working days against a 255-day benchmark. Registration type is listed as EOI (extension of indication pathway context on the TGA listing).
How is the product recorded on the ARTG?
The ARTG entry 470405 for SPEVIGO spesolimab 150 mg/mL pre-filled syringe shows an ARTG date of 3 February 2026 and lists spesolimab as the active ingredient. That entry confirms a marketed presentation on the Australian Register of Therapeutic Goods aligned with the February 2026 registration date.
Readers should treat ARTG inclusion as legal authorisation to supply the registered goods in Australia, not as a statement of hospital formulary status or Pharmaceutical Benefits Scheme reimbursement.
Which clinical programmes underpin flare prevention?
ClinicalTrials.gov record NCT04399837 (Effisayil 2) describes a completed Phase 2b, randomised, double-blind, placebo-controlled study of subcutaneous spesolimab to prevent GPP flares in adolescents and adults aged 12–75 years. The registry lists 123 participants, start date 4 June 2020, and completion 23 November 2022, with primary endpoint time to first GPP flare up to 48 weeks.
A PubMed-indexed Lancet report of Effisayil 2 states that by week 48, flares occurred in 3 of 30 patients (10%) on high-dose spesolimab versus 16 of 31 (52%) on placebo, with a hazard ratio of 0.16 (95% CI 0.05–0.54; p=0.0005) for time to flare. The trial ran at 60 sites in 20 countries and enrolled a majority Asian population (79 of 123; 64%).
What did earlier flare-treatment data show?
ClinicalTrials.gov record NCT03782792 (Effisayil 1) documents the randomised, placebo-controlled study of intravenous spesolimab in adults with moderate-to-severe GPP flares (53 participants). That programme supported earlier adult flare-treatment authorisations in major markets and is the acute-flare counterpart to the subcutaneous maintenance design in Effisayil 2.
Boehringer Ingelheim’s 30 January 2023 Business Wire release on Effisayil 2 stated that the study met its primary and key secondary endpoints for flare prevention up to 48 weeks, with safety described as consistent with prior spesolimab trials. Company wire copy is not a substitute for the TGA decision text.
Why this matters for APAC dermatology access
GPP is a rare, potentially life-threatening autoinflammatory skin disease. Expanding the Australian label from adult flare treatment toward adolescent eligibility and explicit flare prevention changes how clinicians can plan maintenance IL-36 receptor blockade for patients who clear after a flare.
Related NovaPharmaNews APAC coverage includes TGA Australia drug approval context, Leqembi real-world LEADER study notes, and Insilico–Bora alliance analysis.
What remains unproven?
The TGA pages cited here do not publish full Australian Public Assessment Report narrative for the February 2026 decision in the excerpts used for this brief. Long-term Australian post-marketing outcomes, PBS listing status, and real-world adolescent uptake are not documented on those registration pages. Efficacy percentages above come from the published Effisayil 2 trial report, not from a new Australian outcomes study.
Frequently Asked Questions
What did the TGA register for SPEVIGO in February 2026?
The TGA lists SPEVIGO (spesolimab), sponsored by Boehringer Ingelheim Pty Ltd, as registered on 3 February 2026 for generalised pustular psoriasis (GPP), including treatment and prevention of flares, in adults and adolescents from 12 years of age weighing at least 40 kg.
Which trials support spesolimab’s GPP flare-prevention use?
ClinicalTrials.gov lists Effisayil 2 (NCT04399837) as a completed Phase 2b study in 123 adolescents and adults testing subcutaneous spesolimab for GPP flare prevention over 48 weeks. Effisayil 1 (NCT03782792) evaluated intravenous spesolimab in acute GPP flares.
Does ARTG entry alone confirm PBS listing or local supply timing?
No. TGA registration and ARTG inclusion authorise supply under Australian therapeutic goods law. PBS listing, hospital formulary uptake, and commercial launch timing are separate decisions and are not stated on the TGA registration page cited here.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for spesolimab.
Unlock full calendar →Boehringer Ingelheim pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Investor brief
Download a one-page summary of regulatory impact and competitive context.
Explore drug hub →Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
This article follows our editorial standards. Report a correction via editorial contact.
